CD274 and neoplasm: These benefits of neoadjuvant immunotherapy have been interpreted to be associated with the enhanced systemic anti‐tumour effects and reinvigorated responsive T cells against tumour antigens upon blockade of the PD‐1/PD‐L1 axis, eliminating micro‐metastatic tumour cells which may lead to postsurgical relapse.4